Pharma BD Deal Intelligence

Sumitomo Pharma / Sumitovant Biopharma / Myovant Sciences Ltd.

2022 · Acquisition/Merger · $1.7B · Complete

Sumitovant Biopharma agreed to acquire all outstanding Myovant shares it did not already own (Sumitomo held ~52%) at $27.00/share cash, valuing the minority at $1.7B and total company at $2.9B. The deal was a definitive agreement on Oct 24, 2022 (revised up from prior offer). Note: existing DB Sumitovant/Myovant record dated 2022-12-16 captures a different milestone; verify if the Oct 24 definitive agreement vs. Dec 16 are duplicates before merging.

Key facts

• Announced Oct 24, 2022
• Closed Mar 10, 2023
• Deal value $1.7B
• Deal type Acquisition/Merger
• Therapeutic area Uterine fibroids/endometriosis; advanced prostate cancer
• Indications Uterine fibroids/endometriosis; advanced prostate cancer
• Key assets Myfembree (relugolix combo); Orgovyx (relugolix)
• Mechanism Oral GnRH receptor antagonist (relugolix)

← Browse all deals  ·  How we score deals